Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Unique Headline: AbbVie Inc. NYSE:ABBV Dominated by Institutional Shareholders

January 11, 2025
AbbVie Inc., a leading pharmaceutical company listed on NYSE under the ticker symbol ABBV, is largely owned and controlled by institutional shareholders, who hold 73% of the company's shares, according to Yahoo Finance. This indicates the confidence and trust institutional investors have in AbbVie's growth potential and long-term prospects.

Despite the strong institutional ownership, Seeking Alpha reports that AbbVie's stock is being undervalued in the market. The stock is deemed as unfairly cheap, presenting an opportunity for potential investors. This assessment suggests that AbbVie has significant growth potential that is not fully reflected in its current stock price.

CWA Asset Management Group LLC, a prominent investment firm, recently sold some of its shares in AbbVie Inc. This move might raise concerns, but it is important to note that such sales are common among institutional investors who often rebalance their portfolios. The company's overall confidence in AbbVie's performance remains intact.

AbbVie's stock experienced a marginal decline of -0.32 recently. However, it is crucial to consult professionals from Stocks Prognosis for an accurate forecast on the future movement of AbbVie's stock. These experts can provide valuable insights and recommendations to potential investors, helping them make informed decisions.

It is important to consider AbbVie Inc.'s strong institutional ownership, the perception of its undervalued stock, and the recent stock movement when evaluating investment opportunities. Seeking advice from professionals at Stocks Prognosis can further enhance the decision-making process.
If you want to leave a comment, then you need Login or Register





Other data for ABBV

Related data

ABBVMarch 22, 2025AbbVie ABBV Stock Moves -0.29: What You Should Know  ~1 min.

AbbVie Inc., a renowned pharmaceutical company, has recently experienced a slight decrease in stock movement. As an investor, it is essential to keep track of such fluctuations....

ABBVMarch 20, 2025AbbVie Inc. ABBV is Experiencing Global Investor Interest: A Look into the Company's Success Story  ~2 min.

AbbVie Inc., a renowned pharmaceutical company, has been making waves in the global market, attracting significant attention from investors worldwide....

ABBVMarch 19, 2025AbbVie Inc. ABBV: A Higher-Yielding Healthcare Play That Continues to Shine  ~1 min.

AbbVie Inc., a renowned pharmaceutical company, is steadily gaining the attention of investors. With its continuous success in the healthcare industry, AbbVie has become a top choice for hedge funds....

ABBVMarch 18, 2025The Zacks Analyst Blog Highlights AbbVie, Lockheed Martin, Dell, and Hamilton Beach Brands  ~1 min.

According to a recent analysis by Zacks, AbbVie Inc. (ABBV) is considered one of the top healthcare stocks to invest in....

ABBVMarch 14, 2025AbbVie Inc. ABBV is Attracting Investor Attention: Here is What You Should Know  ~2 min.

AbbVie Inc. (ABBV) has been grabbing the attention of investors recently with its impressive performance in the healthcare sector....

ABBVMarch 10, 2025ABBVIE INC. Hits Price Target Forecast with 15.28% Profit – A Triumph for QuantWave's Analytics  ~1 min.

ABBVIE INC. achieved a significant milestone as it hit the price target forecast set by QuantWave, resulting in a profit of 15.28%....

ABBVMarch 10, 2025ABBVIE INC. Hits Price Target Forecast on QuantWave with 15.28% Profit Margin  ~1 min.

AbbVie Inc. (ABBV) has successfully reached the price target forecast on QuantWave, signaling a profitable long position for investors. The forecast, initiated on August 13, 2024, at a price of $184....

ABBVFebruary 28, 2025QuantWave Forecast Success: ABBVIE INC. Hits Price Target with 13.87% Profit  ~2 min.

On July 30, 2024, QuantWave issued a long signal for ABBVIE INC. stock when it was priced at 180.33 $....

ABBVFebruary 28, 2025ABBVIE INC. Hits Price Target Forecast with 25.02% Profit on QuantWave  ~1 min.

QuantWave, the automated forecasting platform, recently achieved a significant milestone with its price target forecast for ABBVIE INC....

ABBVFebruary 27, 2025ABBVIE INC. Hits Price Target Forecast with 22.62% Profit Margin  ~1 min.

QuantWave's forecast for ABBVIE INC. proved to be spot on as the stock reached the predicted target with a profitable outcome of 22.62%....

ABBVDecember 3, 2024AbbVie Inc. Continues to Impress with Strong Financial Performance  ~1 min.

With 73% ownership in AbbVie Inc., institutional investors have a lot riding on the business, making it one of the most attractive pharmaceutical stocks to buy....

ABBVJanuary 9, 2025AbbVie Inc. NYSE:ABBV Captivates Institutional Shareholders with 73% Ownership  ~2 min.

AbbVie Inc., the renowned pharmaceutical company listed on NYSE under the ticker symbol ABBV, boasts an impressive 73% ownership by institutional shareholders....

ABBVOctober 28, 2024AbbVie Inc. Attracts Investor Attention with 73% Institutional Ownership  ~1 min.

AbbVie Inc. (NYSE:ABBV), a leading pharmaceutical company, has caught the attention of investors due to its high institutional ownership....

ABBVJanuary 10, 2025AbbVie Inc. NYSE:ABBV Shareholders Benefit from Increased Dividends  ~1 min.

AbbVie Inc., a leading pharmaceutical company, has announced that its shareholders will receive a larger dividend this year compared to the previous year....

ABBVOctober 29, 2024ABBVIE INC. Attracts Investor Attention with Recent Acquisition of Aliada Therapeutics  ~2 min.

With 73% institutional ownership, AbbVie Inc. (NYSE:ABBV) has become a favorite among the big guns in the industry, as reported by Yahoo Finance....